United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g

United States - English - NLM (National Library of Medicine)

marnel pharmaceuticals, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 120 mg - urimar-t™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urimar-t™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urimar-t™ has not been reported and due to the nature of its ingredients, abuse of urimar t™ is not expected.

United States - English - NLM (National Library of Medicine)

vilvet pharmaceuticals inc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr), methylene blue anhydrous (unii: 8nap7826ub) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81 mg - vilevev mb is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections and antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. vilevev mb is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of vilevev mb has not been reported and due to the nature of its ingredients, abuse of vilevev mb is not expected.

United States - English - NLM (National Library of Medicine)

avkare - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81 mg -  uroav-81 tablets is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-81 tablets is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

United States - English - NLM (National Library of Medicine)

mission pharmacal company - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - utira ® -c tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of utira ® -c tablets has not been reported and due to the nature of its ingredients, abuse of utira ® -c tablets is not expected.

United States - English - NLM (National Library of Medicine)

vilvet pharmaceuticals inc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr), methylene blue anhydrous (unii: 8nap7826ub) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 118 mg - vilamit mb is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. vilamit mb is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of vilamit mb has not been reported and due to the nature of its ingredients, abuse of vilamit mb is not expected.

United States - English - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - methenamine hippurate - oral tablet - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - methenamine hippurate - oral tablet - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

brown & burk uk ltd - methenamine hippurate - oral tablet - 1gram